LeMaitre Vascular (LMAT) – Investment Analysts’ Weekly Ratings Changes

LeMaitre Vascular (NASDAQ: LMAT) recently received a number of ratings updates from brokerages and research firms:

  • 7/9/2018 – LeMaitre Vascular had its price target raised by analysts at Canaccord Genuity from $31.00 to $35.00. They now have a “hold” rating on the stock.
  • 6/28/2018 – LeMaitre Vascular was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/25/2018 – LeMaitre Vascular is now covered by analysts at Lake Street Capital. They set a “buy” rating and a $45.00 price target on the stock.
  • 6/22/2018 – LeMaitre Vascular was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/21/2018 – LeMaitre Vascular was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 6/15/2018 – LeMaitre Vascular was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 6/8/2018 – LeMaitre Vascular is now covered by analysts at Roth Capital. They set a “buy” rating and a $38.00 price target on the stock.
  • 6/8/2018 – LeMaitre Vascular was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

LeMaitre Vascular stock traded up $0.17 during trading hours on Wednesday, reaching $36.45. The company had a trading volume of 100,847 shares, compared to its average volume of 153,753. The stock has a market capitalization of $695.44 million, a P/E ratio of 42.38, a price-to-earnings-growth ratio of 2.21 and a beta of 0.57. LeMaitre Vascular Inc has a 12-month low of $27.90 and a 12-month high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 EPS for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.02). The company had revenue of $25.99 million during the quarter, compared to analysts’ expectations of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. LeMaitre Vascular’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $0.16 earnings per share. sell-side analysts forecast that LeMaitre Vascular Inc will post 1.09 earnings per share for the current year.

In other news, Chairman George W. Lemaitre sold 4,672 shares of the business’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $33.43, for a total transaction of $156,184.96. Following the transaction, the chairman now directly owns 3,165,709 shares of the company’s stock, valued at $105,829,651.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman George W. Lemaitre sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $37.07, for a total value of $556,050.00. Following the transaction, the chairman now directly owns 3,073,802 shares in the company, valued at $113,945,840.14. The disclosure for this sale can be found here. Insiders sold a total of 120,598 shares of company stock worth $4,144,663 over the last ninety days. Insiders own 20.30% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. increased its stake in shares of LeMaitre Vascular by 73.8% during the first quarter. Victory Capital Management Inc. now owns 5,076 shares of the medical instruments supplier’s stock valued at $184,000 after buying an additional 2,156 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $215,000. Citadel Advisors LLC purchased a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $241,000. Advisor Group Inc. increased its stake in shares of LeMaitre Vascular by 28.3% during the fourth quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock valued at $223,000 after buying an additional 1,550 shares during the period. Finally, MetLife Investment Advisors LLC purchased a new position in shares of LeMaitre Vascular during the fourth quarter valued at approximately $244,000. 72.87% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Receive News & Ratings for LeMaitre Vascular Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply